KR850007275A - 기능성 인체인자 ⅷ의 제조방법 - Google Patents

기능성 인체인자 ⅷ의 제조방법 Download PDF

Info

Publication number
KR850007275A
KR850007275A KR1019850002651A KR850002651A KR850007275A KR 850007275 A KR850007275 A KR 850007275A KR 1019850002651 A KR1019850002651 A KR 1019850002651A KR 850002651 A KR850002651 A KR 850002651A KR 850007275 A KR850007275 A KR 850007275A
Authority
KR
South Korea
Prior art keywords
human factor
functional
recombinant
factor vii
factor viii
Prior art date
Application number
KR1019850002651A
Other languages
English (en)
Inventor
제프리 케이폰 외 3 다니엘
Original Assignee
월터 에이취. 드레거
제넨테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24410850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850007275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 월터 에이취. 드레거, 제넨테크 인코포레이티드 filed Critical 월터 에이취. 드레거
Publication of KR850007275A publication Critical patent/KR850007275A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

기능성 인체인자 Ⅷ의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 응고 케스케이드(2)의 다이아그람 도식이고, 제2도는 염화테트라메틸암모늄(“TMACL”)과 6XSSC내의 DNA응용온도의 변화도표이고, 제3도는 탐침입자 8.3으로 인자Ⅷ 유전자를 추적하는 것이고.

Claims (22)

  1. 재조합 기능성 인체인자 Ⅷ.
  2. 본원적으로 순수한 형태의 인체기능 인자Ⅷ.
  3. 기능성 인체인자 Ⅷ 또는 기능성 인체인자 Ⅷ유도체 암호화하는 서열로 구성되는 것이 특징인 DNA단리물.
  4. 세포의 형질감염 배양체에서 제3항에 따른 DNA서열을 표함할 수 있는 복제가능한 표면벡터.
  5. 벡터 pAML3P.8cl.
  6. 세포가 제4항 또는 제5항의 표현벡터로 형질감염된 재조합 기능성 인체인자Ⅷ을 생성할 수 있는 세포배양지.
  7. 제6항에 있어서, 새끼 햄스터 신장(BHK)세포를 형질감염시켜서 얻은 세포배양지.
  8. 인체인자 Ⅷ 또는 기능성 인체인자 Ⅷ유도체 암호화하는 DNA를 재조합숙주 세포내에서 표현시키는 것이 특징인 방법.
  9. 기능성 인체인자 Ⅷ 또는 인체인자 Ⅷ 유도체에 대응하는 하나이상의 성분으로 구성되는 것이 특징인 조성물.
  10. 제9항에 있어서, 인체인자Ⅷ 또는 인체인자 Ⅷ 유도체가 재조합 숙주세포에 의하여 생성되는 조성물.
  11. 제9항에 있어서, 인체인자 Ⅷ 유도체에 대응하는 하나이상의 성분으로 구성되는 조성물.
  12. 인자 Ⅷ 응고활성체가 부족한 환자에게 치료학적으로 유효한 양의 기능성 재조합 인체인자 Ⅷ 또는 기능성 인체인자 Ⅷ 유도체를 투여하는 것이 특징인 인자Ⅷ 응고활성체가 부족한 환자를 치료하는 방법.
  13. 제12항에 있어서, 투여된 물질이 기능성 재조합 인체인자 Ⅷ로 구성되는 방법.
  14. 제12항에 있어서, 투여된 물질이 기능성 인체인자 Ⅷ 유도체로 구성되는 방법.
  15. 제12항의 방법에서 사용하기에 적합한 형태의 재조합 인체인자 Ⅷ.
  16. 제15항에 있어서, 계약상 허용가능한 담체와의 혼합물인 인 재조합 인체이자Ⅷ.
  17. 벡터 pGcos4를 이용하는 게놈처리 방법.
  18. 벡터 pGcos4.
  19. 절개 공급인자 부위가 앞에 있고 절개 수용인자 부위가 연이어진 인트론, 이 인트론에 삽압되어 있고 필요한 폴리펩티드의 필수암호화서열을 지닌 DNA단편으로 구성되어 있으며, 형질감염된 진핵세포배리내에서 전사시 인 트론이 없는 상기 삽입 DNA단편의 대응하는 단편을 제공할 수 있는 재조합 DNA표현벡터.
  20. pESVDA.
  21. 제19항과 제20항에 따르는 벡터로 형질감염된 진핵세포배지.
  22. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850002651A 1984-04-20 1985-04-19 기능성 인체인자 ⅷ의 제조방법 KR850007275A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60231284A 1984-04-20 1984-04-20
US602312 1984-04-20

Publications (1)

Publication Number Publication Date
KR850007275A true KR850007275A (ko) 1985-12-02

Family

ID=24410850

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850002651A KR850007275A (ko) 1984-04-20 1985-04-19 기능성 인체인자 ⅷ의 제조방법

Country Status (23)

Country Link
EP (2) EP0160457B1 (ko)
JP (2) JP2799338B2 (ko)
KR (1) KR850007275A (ko)
AR (1) AR241314A1 (ko)
AT (1) ATE60087T1 (ko)
AU (2) AU601358B2 (ko)
CA (2) CA1341468C (ko)
DE (1) DE3581312D1 (ko)
DK (1) DK164876C (ko)
ES (1) ES8607397A1 (ko)
FI (1) FI86885C (ko)
GR (1) GR850947B (ko)
HK (1) HK8395A (ko)
HU (1) HU202275B (ko)
IE (1) IE57677B1 (ko)
IL (1) IL74909A (ko)
LU (1) LU88546I2 (ko)
MY (1) MY102029A (ko)
NL (1) NL940016I2 (ko)
NO (1) NO174934C (ko)
NZ (1) NZ211824A (ko)
PT (1) PT80292B (ko)
ZA (1) ZA852864B (ko)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
JPH07106156B2 (ja) * 1983-10-28 1995-11-15 ジェネティックス、インスティチュ−ト ファクタ−▲ｖｉｉｉ▼および関連生産物の製造
US4716117A (en) * 1984-10-26 1987-12-29 Chiron Corporation Monoclonal antibodies to factor VIIIC
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
US5004804A (en) * 1984-01-12 1991-04-02 Nordisk Gentofte Method and composition for preparation of factor VIIIC
DK165506C (da) * 1984-01-12 1993-04-19 Chiron Corp Proteinpraeparat med koagulationsaktivitet samt fremgangsmaade til fremstilling deraf
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
EP0182448A3 (en) * 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
EP0218712B1 (en) * 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
FR2599754B1 (fr) * 1986-06-06 1989-12-29 Transgene Sa Procede de preparation de facteur viii a partir de cellules de mammiferes
ATE63335T1 (de) 1986-07-11 1991-05-15 Miles Inc Herstellung von rekombinantem protein.
NO872932L (no) * 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
GB2197321B (en) * 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
AU606925B2 (en) * 1987-01-30 1991-02-21 Biogen, Inc. A method for producing factor viii in high yield
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JP2791418B2 (ja) 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
FR2642767B1 (fr) * 1989-01-19 1993-10-01 Transgene Sa Vecteurs d'expression de proteines heterologues dans les cellules eucaryotes, lignees cellulaires obtenues et procede pour leur preparation
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
US6008193A (en) * 1990-03-02 1999-12-28 Bio-Technology General Corp. Methods of using human von Willebrand factor GPIb binding domain polypeptides
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
AT405740B (de) * 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
CA2404163C (en) * 2000-03-22 2009-09-29 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
US7220718B2 (en) 2001-08-03 2007-05-22 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
AU2002358047A1 (en) * 2001-11-28 2003-06-10 Sandoz Ag Method for producing a recombinant polypeptide
JP2005532057A (ja) 2002-07-09 2005-10-27 バクスター・インターナショナル・インコーポレイテッド 細胞を培養するための動物性タンパク質非含有培地
EP2298926A1 (en) 2003-09-30 2011-03-23 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP3409296A1 (en) 2005-04-07 2018-12-05 The Trustees of the University of Pennsylvania Method of increasing the function of an aav vector
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
EP2522717B1 (en) 2006-01-04 2014-04-02 Baxter International Inc Oligopeptide-free cell culture media
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
SG10201908848RA (en) 2010-03-29 2019-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
PL2675902T3 (pl) 2011-02-17 2019-08-30 The Trustees Of The University Of Pennsylvania Kompozycje i sposoby do zmieniania specyficzności względem tkanki i poprawy transferu genu z udziałem aav9
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
US10058624B2 (en) 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
CN111504887B (zh) * 2020-05-09 2023-05-09 苏州四正柏生物科技有限公司 一种溶血素及其制备方法
US20240043494A1 (en) 2020-08-07 2024-02-08 Amicus Therapeutics, Inc. Vesicle Targeting Proteins And Uses Of Same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JP2625412B2 (ja) * 1982-08-04 1997-07-02 ブリティッシュ・テクノロジー・グループ・リミテッド ヒト第９因子ポリペプチドをコードするｃｄｎａ
CA1341506C (en) * 1983-03-31 2006-06-06 Theodore S. Zimmerman Factor viii coagulant polypeptides and monoclonal antibodies to them
JPH07106156B2 (ja) * 1983-10-28 1995-11-15 ジェネティックス、インスティチュ−ト ファクタ−▲ｖｉｉｉ▼および関連生産物の製造
DK165506C (da) * 1984-01-12 1993-04-19 Chiron Corp Proteinpraeparat med koagulationsaktivitet samt fremgangsmaade til fremstilling deraf
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPS60224492A (ja) * 1984-04-24 1985-11-08 Yuu Honshiyo 異種遺伝子の結合法

Also Published As

Publication number Publication date
EP0160457A1 (en) 1985-11-06
NO174934C (no) 1994-08-03
IL74909A (en) 1992-01-15
JPS60243023A (ja) 1985-12-03
PT80292A (en) 1985-05-01
DK164876B (da) 1992-08-31
ATE60087T1 (de) 1991-02-15
JP2777043B2 (ja) 1998-07-16
LU88546I2 (fr) 1995-03-01
FI851497A0 (fi) 1985-04-15
FI86885C (fi) 1992-10-26
GR850947B (ko) 1985-07-17
CA1341468C (en) 2004-12-14
AU601358B2 (en) 1990-09-13
EP0385558A3 (en) 1990-12-27
JPH0640942A (ja) 1994-02-15
EP0385558A2 (en) 1990-09-05
NL940016I1 (nl) 1994-10-17
ES8607397A1 (es) 1986-06-01
IE57677B1 (en) 1993-02-24
DK176885A (da) 1985-10-21
JP2799338B2 (ja) 1998-09-17
HUT37654A (en) 1986-01-23
FI851497L (fi) 1985-10-21
MY102029A (en) 1992-02-29
ZA852864B (en) 1986-12-30
DE3581312D1 (de) 1991-02-21
NL940016I2 (nl) 2000-08-01
NO174934B (no) 1994-04-25
PT80292B (pt) 1987-10-20
CA1341395C (en) 2002-10-22
HK8395A (en) 1995-01-27
EP0160457B1 (en) 1991-01-16
IL74909A0 (en) 1985-07-31
HU202275B (en) 1991-02-28
AU5295890A (en) 1990-08-30
NZ211824A (en) 1991-05-28
IE850998L (en) 1985-10-20
AU4134585A (en) 1985-10-24
NO851563L (no) 1985-10-21
AR241314A1 (es) 1992-05-29
DK176885D0 (da) 1985-04-19
FI86885B (fi) 1992-07-15
ES542296A0 (es) 1986-06-01
DK164876C (da) 1993-01-18

Similar Documents

Publication Publication Date Title
KR850007275A (ko) 기능성 인체인자 ⅷ의 제조방법
NO173741C (no) DNA-sekvens for modifisert protein C, vektor inneholdende denne, patte-dyrceller transfektert med vektorer, og fremgangsmaate for fremstilling av nevnte protein
NO176921C (no) Genteknologisk fremgangsmåte for fremstilling av et tPA-lignende protein, samt vertscelle som er i stand til å uttrykke et slikt protein
KR890000666A (ko) 응고활성을 갖는 인자 viii:c-형 분자
KR900702019A (ko) 효소원 또는 피브린 특이성을 갖는 조직 플라스미노겐 활성제
ATE179754T1 (de) Verfahren zur herstellung von thrombin
ATE93272T1 (de) Expression von protein c.
KR910003094A (ko) 흡혈박쥐속(Vampire bat) 타액 플라스미노겐 활성인자
DE3780179D1 (de) Herstellung von menschlichem erythropoietin.
KR910021477A (ko) 인체 단백질 c의 글리코실화 돌연변이체의 발현을 위한 벡터 및 화합물
KR880009991A (ko) 항혈액응고작용을 갖는 폴리펩티드
KR890000521A (ko) 변형된 성장 인자 도메인을 갖는 조직 플라즈미노겐 활성제 동족체
DE69227921D1 (de) Herstellung von Proteinen mittels Protein 7B2
Sekiguchi et al. Human tissue fibronectin: expression of different isotypes in the adult and fetal tissues
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
KR890005267A (ko) 변형된 플라스미노겐 활성제
ES2181684T3 (es) Promotor del gen epidermico humano.
ES2067221T3 (es) Activador de plasminogeno del tejido que tiene propiedades especificas para la fibrina.
KR880011340A (ko) 하이브리드 세르핀 및 이들이 암호화 dna
DE3752281D1 (de) Stabilisierung von messenger-rns in tierischen zellen
KR910006484A (ko) 아밀로이드 전구체 단백질 프로머터 이를 이용한 아밀로이드 전구체 단백질의 발현 조절 방법 및 이를 이용한 알쯔하이머 병 치료 방법
DE69113049D1 (de) Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
KR880001814A (ko) 비루스성 벡터
KR870008588A (ko) 신규 인체 조직형 플라스미노겐 활성제 폴리펩티드

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application